{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:11:39Z","timestamp":1783350699090,"version":"3.54.6"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study evaluates the risk of dermatologic adverse events (AEs) associated with aromatase inhibitors (AIs) through an analysis of data from the FDA Adverse Event Reporting System (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>FAERS data from Q1 2004 to Q2 2024 were analyzed for dermatologic AEs related to AIs. A disproportionality analysis using reporting odds ratio (ROR) assessed AE risk, and the time to onset of these AEs was examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 21,035,995 AE reports, 2,237 involved skin impairment. Sixty-one preferred terms (PTs) presented positive signals, including nail disorders, onychoclasis, and abnormal hair growth in patients on anastrozole, exemestane, or letrozole. The highest associations were with pseudo cellulitis (ROR = 57.73), anhidrosis (ROR = 48.68), and nail toxicity (ROR = 38.40). Strong associations were observed for anastrozole (ROR = 1.07, 95% confidence interval: 1.03\u20131.11) and exemestane (ROR = 1.1, 95% CI: 1.04\u20131.16), but not for letrozole. Eleven dermatologic PTs had onset times under 50\u00a0days, with the earliest at 2\u00a0days; the latest, skin ulcer, appeared at 241.5\u00a0days with exemestane.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The findings provide substantial evidence of dermatologic AEs associated with AIs, particularly anastrozole and exemestane, emphasizing the importance of dermatologic monitoring during AI therapy and the need for further research into AI-induced dermatologic AEs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1529342","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:38:52Z","timestamp":1747201132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuan-Yuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong-Lian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Yang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Zhou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18334","DOI":"10.1038\/s41598-020-75059-9","article-title":"Increased estrogen to androgen ratio enhances immunoglobulin levels and impairs B cell function in male mice","volume":"10","author":"Aguilar-Pimentel","year":"2020","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1248\/bpb.b19-00156","article-title":"Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS","volume":"42","author":"Ando","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"B4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ijwd.2021.07.002","article-title":"Art of prevention: the importance of dermatologic care when using aromatase inhibitors","volume":"7","author":"Behbahani","year":"2021","journal-title":"Int. J. Womens Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1200\/jco.2001.19.14.3357","article-title":"Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate","volume":"19","author":"Buzdar","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/cncr.10908","article-title":"An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane","volume":"95","author":"Buzdar","year":"2002","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"A460","DOI":"10.1016\/j.autrev.2011.11.014","article-title":"Estrogen metabolism and autoimmunity","volume":"11","author":"Cutolo","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1517\/17425250903540246","article-title":"Letrozole","volume":"6","author":"Dellapasqua","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s1470-2045(18)30116-5","article-title":"Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial","volume":"19","author":"De Placido","year":"2018","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1056\/NEJMoa1414827","article-title":"Letrozole, gonadotropin, or clomiphene for unexplained infertility","volume":"373","author":"Diamond","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"113480","DOI":"10.1016\/j.ejca.2023.113480","article-title":"Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer","volume":"198","author":"Fasching","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijwd.2019.10.003","article-title":"Dermatologic conditions in women receiving systemic cancer therapy","volume":"5","author":"Ferreira","year":"2019","journal-title":"Int. J. Womens Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","article-title":"Endocrine therapy-induced alopecia in patients with breast cancer","volume":"154","author":"Freites-Martinez","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1038\/ncomms6736","article-title":"Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1","volume":"5","author":"Fusi","year":"2014","journal-title":"Nat. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.34332","article-title":"Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis","volume":"152","author":"Gu","year":"2023","journal-title":"Int. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctrv.2018.07.014","article-title":"Personalizing aromatase inhibitor therapy in patients with breast cancer","volume":"70","author":"Hamadeh","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bioorg.2017.02.011","article-title":"Estrogen receptor agonists\/antagonists in breast cancer therapy: a critical review","volume":"71","author":"Jameera Begam","year":"2017","journal-title":"Bioorg Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2000081","DOI":"10.1002\/ardp.202000081","article-title":"Aromatase inhibitors: role in postmenopausal breast cancer","volume":"353","author":"Kharb","year":"2020","journal-title":"Arch. Pharm. Weinh."},{"key":"B21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsbmb.2017.01.009","article-title":"Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: a comprehensive review","volume":"168","author":"Patel","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.clbc.2013.08.011","article-title":"Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2","volume":"13","author":"Pritchard","year":"2013","journal-title":"Clin. Breast Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1155558","DOI":"10.3389\/fphar.2023.1155558","article-title":"Targeting the formation of estrogens for treatment of hormone dependent diseases-current status","volume":"14","author":"Ri\u017ener","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2020.11.038","article-title":"Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer","volume":"145","author":"Robertson","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1468-3083.2010.03803.x","article-title":"Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis","volume":"25","author":"Santoro","year":"2011","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10549-017-4523-y","article-title":"Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial","volume":"167","author":"Sonke","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.steroids.2011.10.013","article-title":"Tissue physiology and pathology of aromatase","volume":"77","author":"Stocco","year":"2012","journal-title":"Steroids"},{"key":"B30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1200\/jop.18.00710","article-title":"Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy","volume":"15","author":"Sussman","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40264-014-0146-y","article-title":"Performance of probabilistic method to detect duplicate individual case safety reports","volume":"37","author":"Tregunno","year":"2014","journal-title":"Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.maturitas.2017.06.026","article-title":"The role of estrogen in cutaneous ageing and repair","volume":"103","author":"Wilkinson","year":"2017","journal-title":"Maturitas"},{"key":"B33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3889\/oamjms.2018.026","article-title":"Segmental erythema multiforme-like drug eruption by aromatase inhibitor anastrozole - first case report and another example of an immunocompromised district","volume":"6","author":"Wollina","year":"2018","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/imj.14422","article-title":"Leukocytoclastic vasculitis associated with use of aromatase inhibitors","volume":"49","author":"Woodford","year":"2019","journal-title":"Intern Med. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.numecd.2021.10.003","article-title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system","volume":"32","author":"Yang","year":"2022","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jare.2016.04.001","article-title":"Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: a review","volume":"7","author":"Zarkavelis","year":"2016","journal-title":"J. Adv. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/biomedicines12081708","article-title":"Adverse event profiles of the third-generation aromatase inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomedicines"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1529342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:38:53Z","timestamp":1747201133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1529342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":37,"alternative-id":["10.3389\/fphar.2025.1529342"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1529342","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1529342"}}